March 2023 in “Clinical, Cosmetic and Investigational Dermatology” This study concluded that both oral and topical spironolactone effectively treat androgenetic alopecia, with topical administration being safer and suitable for any gender, especially when combined with minoxidil.
This study found that finasteride-loaded nanostructured lipid carriers developed for topical application showed satisfactory size, stability, and prolonged drug release, suggesting potential for enhanced delivery in androgenic alopecia treatment.
1 citations
,
July 2022 in “Journal of Drug Delivery Science and Technology” This study found that Spironolactone-loaded ethosomal gels provided superior skin permeation and deposition compared to niosomal gels in rabbit skin, suggesting that ethosomal gels could be a promising formulation for further clinical studies on treating androgenic alopecia.
4 citations
,
December 2021 in “Journal of The American Academy of Dermatology” This study reported a significant increase in the use of spironolactone for treating acne and hidradenitis suppurativa in female adolescents, noting a 2- to 3-fold rise in prescriptions and suggesting improved tolerance compared to adults, though its efficacy in adolescents is less pronounced.
18 citations
,
September 2021 in “Colloids and surfaces. B, Biointerfaces” This study explored the development of polymeric nanoparticles for topical spironolactone delivery, finding that larger nanoparticles (180 nm) enhanced drug targeting to hair follicles significantly more than smaller ones or non-nanoparticle formulations, offering promise for safer acne and alopecia treatments.
15 citations
,
July 2021 in “AAPS PharmSciTech” 
9 citations
,
June 2021 in “International Journal of Pharmaceutics” This study found that polymeric micelle nanocarriers delivered pharmacologically relevant amounts of spironolactone to the epidermis and upper dermis, with higher delivery to pilosebaceous units, suggesting potential for treating glucocorticoid-induced impaired wound healing and pilosebaceous androgen-related skin diseases.
22 citations
,
March 2020 in “Cosmetics” This review discusses the potential of nanotechnology-based formulations for delivering topical minoxidil to improve hair loss treatment outcomes and reports no new clinical results, urging further research into their benefits and safety considerations.
40 citations
,
March 2019 in “Pharmaceutical development and technology” The study found that cyproterone acetate-loaded nanostructured lipid carriers, particularly those with a 300 nm diameter, improved skin penetration and targeted hair follicles more effectively than free cyproterone acetate.
34 citations
,
October 2018 in “Journal of The American Academy of Dermatology” This review discusses hormone-modulating therapies for androgen-mediated cutaneous disorders in women but reports no new clinical results and highlights the need for more rigorous studies.
38 citations
,
November 2016 in “Aaps Pharmscitech” This study found that the nanostructured lipid carrier formulation with a 70:30 solid to liquid lipid ratio significantly increased the dissolution rate, entrapment efficiency, and stability of spironolactone compared to its raw form.
53 citations
,
February 2015 in “Journal of Investigative Dermatology” This study found that inactivating CerS4 in mice led to hair follicle stem cell exhaustion and hair loss, indicating its role in regulating hair regeneration through ceramide composition and signaling pathways.
59 citations
,
January 2015 in “Nanoscale” In this study, polymeric micelles containing retinoic acid were found to improve targeted delivery to hair follicle structures in human skin more efficiently than a marketed retinoic acid gel, suggesting potentially safer and more effective acne treatment.
89 citations
,
November 2014 in “International Journal of Nanomedicine” This study suggests that spironolactone-loaded nanostructured lipid carriers could enhance follicular delivery and offer a more localized treatment for androgenic alopecia, potentially reducing systemic side effects.
6 citations
,
April 2013 in “Journal of Investigative Dermatology” This study reports that spironolactone use was associated with a decreased risk of developing rosacea compared to other diuretics, particularly in current users without previous androgenic skin disease diagnoses.
67 citations
,
August 2007 in “American Journal of Pathology” This study found that overexpression of the mineralocorticoid receptor in a mouse model led to premature epidermal barrier development, keratinocyte apoptosis, and postnatal alopecia, indicating new roles for MR signaling in skin physiology.
182 citations
,
January 2000 in “Drug Development Research” This study found that ethosomal carriers enhanced dermal and transdermal drug delivery more effectively than classic liposomes, improving delivery to deep skin layers and showing potential for treating conditions like herpes labialis and diabetes.
